Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
2015 PR Full Enrollment
2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced that patient enrollment for the Phase 2a clinical trial of ANAVEX 2-73 has been completed ahead of schedule. With the Phase 2a trial now fully enrolled, Anavex expects to release topline data for PART A before the end of the year.
Ray you are right, $1.25 was the purchase price for everyone.
You will have more opportunities to buy in the near future. If someone is buying someone is selling. It was a disaster to the Sellers’s
I prefer to get free shares.
Lol, also AD has not enrolled near 3 patients per day in Anavex AD trial.
Lower lows since reverse split leading to disaster 12/2018.
If is low volume then there is no demand for stock.
Lol if its churn, then there is no demand for the stock despite this News on the way. Price is and has been trending down.
I heard that story since 2015. News is coming. ...News will come and go and the only constant is the share price is about the same.
Let’s hope the patients get better regardless of SP.
Fire Misleading. Nice name and very appropriate.
The 5, 10, 20, 50 and 100 MA plus MACD, momentum and other tech Ind says it’s a SELL.
Yes. Superb outcome on this one.
Congrats.
3.7M shares is Unusual Activity
Biogen is not my company for AD. MS yes. Best wishes to all AD drugs IMO.
I agree Biogen Cherry picks to high heavens.
IMO the host were looking for a reversal of AD and the findings is a slowing of the decline. Two different outcomes and hence the responses.
Anavex started AD a year ago. Where’s my stoppage? Better yet can we get an update on enrollment.
I watched it live. Given the need to dose more patients at the higher dosage, I believe he said all he could at this point. CEOs are bullish in nature and based upon the constraints he was cautiously optimistic. The conversations with the FDA fuels the optimism. IMO.
I’m not investing any more money in Biogen but apparently others believe the storyline.
Biogen’s CEO appearance on CNBC the day after making a profound announcement after the March debacle is bullish IMO. Just showing up on CNBC displayed his confidence. Now I’m not saying they will be successful but he believes what he is being told. It is clear from the interview, the FDA is listening.
I agree.
Anavex is easily manipulated. All stocks can be manipulated.
BlackRock also owns Neurotrope if that means anything.
In other words, Blackrock invest in failed trials.
Trading halted.
That’s great news. I opened a position on 10/4. I will consider adding.
They didn’t waste much time going from the 2a to 2b.
I do options unfortunately I was on the wrong side of the equation on this one.
I’m planning on buying some more October contracts if no news by the 16th.
Biogen and other recent failures has only encouraged more shorts.
99.6% of AD drugs fail. The trend for AD has not encouraged investors to go long.
IMO of course.
I’m thinking the shorts are so arrogant that they are not using options to provide some insurance.
Approximately 1 million shorts now. The SP might be really interesting with only 13 million shares outstanding.
(It’s been mentioned before that warrants will not necessarily be cashed in right away.)
Options market predicting spike in SP.
https://finance.yahoo.com/amphtml/news/options-market-predicting-spike-neurotrope-144102889.html
Family after family requested to stay on the drug because caregivers were seeing benefits.
Listen between minute 41:10 to 41:30 and Dr states families are pleading to stay on Neurotrope drug. http://noble.mediasite.com/mediasite/Play/911da4f57eff4257a83b9711230158831d?catalog=6f8e7abd-96e3-462f-8035-f48126f80846
This board is up to 90 followers now and it’s the most active MB.
Not exactly mainstream.
Doc,
Is your time estimate below still the same?
“
Patients are observed for 30 more days as part of the protocol, so the study should be complete 6/27/19 +/- 1-3 days. Study completion should get a PR the next day so we should know for certain by 6/28/19 or 7/1/2019 at the latest. Topline release should be 6-10 weeks later, 8/8/19 to 9/5/19.”
Did the July 15 PR change anything?
NEW YORK, July 15, 2019 /PRNewswire/ -- NeurotropeInc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced that the Company has concluded data collection in its confirmatory Phase 2 double blind, placebo controlled clinical trial of Bryostatin-1 in the treatment of moderately severe to severe AD.
Thanks
Superb Audio. It’s been 7 weeks since our trial ended and I wonder when this was recorded. Dr Alkon sounded extremely upbeat. Loved the fact that we have other compounds that are in the wings that are just as good if not better.
Lol. Dr McFarlane stated
The study will be
recruiting throughout 2019 and most likely 2020 and into early 2021.
Study is 48 weeks long. 2022 at earliest.
DUH. Thanks N2
This is a long long long hold for AD.
Anavex having problems recruiting in AD. ( Added Dr notes)
Trial is 450 patients. First patient dosed 8/28/18. Recruiting at 16 sites. Other sites enroll 7 to 10 patients. #1 site is at 31 goal is 50. Dr said recruiting will go into early 2021.
Math not adding up to 450.
Give #1 site 50 which is top end of goal.
Give the other 15 sites top end of their goal of 10 for 150 total.
That’s only 200 patients total.
Looks like we are 250 patients short and again Dr has already admitted recruiting in 2021.
Sorry this news is not good. Drs math is not adding up.
ANAVEX trial- A phase 2b/3, double-blind, randomised, placebocontrolled 48-week safety and efficacy trial of ANAVEX2-73 for the
treatment of Alzheimer’s disease
Associate Professor Macfarlane’s study team has been
involved in testing the ANAVEX2-73 molecule since 2014
and were heavily involved in writing and editing the
previous phase 2a, and current phase 2b/3, protocols.
ANAVEX2-73 is a novel compound that is thought to act on
the sigma 1 intracellular receptor.
Its mode of action is unique in that most (if not all) other
molecules developed thus far to treat Alzheimer’s Disease target
the removal of a single type of toxic protein (either beta amyloid
or Tau). In contrast, ANAVEX2-73 is thought to remove all forms of
misfolded proteins from brain cells.
While involved in the phase 2a study, Associate Professor
Macfarlane and his team saw positive (and at times drastic)
increases in cognition and functioning in study participants, and
are pleased to be involved in the phase 2b/3 study. The study will be
recruiting throughout 2019 and most likely 2020 and into early 2021.
Some key achievements of the HammondCare site in relation to
this study include:
1. Associate Professor Stephen Macfarlane has been appointed
as the global study lead for this study
2. The Malvern site was the first site in the world to be initiated
3. Ours is the global No.1 recruiting site (most sites average 7-10
patients per study, whilst Malvern already has 31 patients on
study and aims to recruit 40-50 patients)
4. This trial is currently being conducted at over 15 sites globally
and will run for another 24 months
Report TOS
Moderate
Dr McFarlane math does not equal 450. Sorry folks. We said it before. Not enough sites and AD is years away.
We already discussed the fact that Harald has only worked with companies that have failed in the AD space.
I’ll stick with my $100k plus investment in $NTRP. Thanks
I’m adding NTRP shares and more interested in Neurotrope research.